Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bioventus Inc.

Get SEC filing alerts via email and in your feed for Bioventus Inc.

BVS

Bioventus Inc.

About Bioventus Inc.

Bioventus Inc. is a global medical device company specializing in musculoskeletal health solutions. Its core business includes three segments: Pain Treatments (hyaluronic acid injections and peripheral nerve stimulation devices), Surgical Solutions (ultrasonic surgical systems and bone graft substitutes), and Restorative Therapies (ultrasound bone stimulation for fracture healing). Bioventus serves physicians and healthcare providers worldwide, offering clinically proven products that relieve pain, enhance surgical outcomes, and support bone repair.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bioventus Inc.

1
1
Bioventus Inc. Bioventus Reports 6.6% Net Sales Increase to $132.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Bioventus Inc. Bioventus Reports 0.9% Sales Decrease but Achieves Net Income Turnaround in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Bioventus Inc. Bioventus Reports Q3 2025 Financial Results with Improved Profitability Despite Slight Sales Decline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bioventus Inc. Bioventus Reports $147.7 Million Revenue, Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bioventus Inc. Bioventus Reports $123.9 Million in Q1 2025 Net Sales, Down 4.5% Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Bioventus Inc. Bioventus Reports $573.3 Million in Net Sales for Fiscal Year 2024, Significant Loss Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Bioventus Inc. Bioventus Reports 15% Revenue Growth, Improved Gross Profit and Operating Income in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments